/filters:format(webp)/prod01/channel_262/queen-mary-university-of-london/media/qmul/media/news/items/fmd/Shot-of-a-doctor-showing-a-patient-some-information-on-a-digital-tablet-stock-photo-640.png)
A doctor showing a patient some information on a digital tablet
The study, published in eClinicalMedicine, estimates that around 965 new cancer cases currently occur each year among transgender and gender-diverse people in England. This could rise to approximately 1,739 cases in five years and 2,257 within 10 years.
The research, believed to be the first to estimate annual cancer cases in this population in England, combined national cancer statistics, population data and existing evidence on the effects of gender-affirming healthcare.
Breast cancer was estimated to be the most common cancer, accounting for around 19% of cases, followed by colorectal cancer (12%) and lung cancer (11%).
The researchers also explored how access to gender-affirming treatments, including hormone therapy and surgery, could affect future cancer cases. Their modelling suggests that access to planned gender-affirming care could reduce the projected number of annual cases in 10 years by approximately 11%.
Dr Alison Berner, lead author and Clinical Senior Lecturer in Medical Oncology at Queen Mary, said:
“Our research suggests that the number of cancer cases among transgender and gender-diverse people in England could more than double over the next decade. This highlights an important and often overlooked area of cancer care. As this population ages, we need to ensure cancer services are prepared to meet patients’ needs and that everyone can access appropriate screening diagnosis and treatment.”
Dr Chloe Pasin, co-lead author and postdoctoral researcher at Queen Mary, said:
“Cancer care is not one-size-fits-all. Our findings suggest that gender-affirming treatments could reduce the likelihood of developing some cancers, while potentially increasing the risk of others. Understanding these differences is essential to care. But we also need better data to build a clearer picture of cancer risks among transgender and gender-diverse people and make sure their needs are not overlooked.”
The researchers emphasise that the findings are based on estimates and modelling rather than directly observed outcomes. They hope the study will help inform future cancer service planning, healthcare professional training and screening policies, alongside improvements in how cancer data is collected.
To find out more about Queen Mary's research, sign up for .